Walleye Capital LLC Has $2.88 Million Holdings in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Walleye Capital LLC reduced its stake in KalVista Pharmaceuticals by 6.9% in Q1, selling 18,582 shares and holding 249,161 shares valued at approximately $2.87 million.
• KalVista Pharmaceuticals reported a substantial earnings miss, with an EPS of ($3.69) compared to the analysts' expectation of ($0.83).
• Analyst ratings for KalVista are favorable, with price targets increased to between $20.00 and $27.00, and a consensus rating of "Buy".

Walleye Capital LLC lessened its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 6.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 249,161 shares of the specialty pharmaceutical company's stock after selling 18,582 shares during the quarter. Walleye Capital LLC owned approximately 0.50% of KalVista Pharmaceuticals worth $2,875,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in KALV. Boxer Capital Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $13,467,000. Octagon Capital Advisors LP acquired a new position in KalVista Pharmaceuticals in the 4th quarter valued at approximately $11,604,000. Frazier Life Sciences Management L.P. increased its stake in KalVista Pharmaceuticals by 32.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after buying an additional 1,200,000 shares during the period. Stempoint Capital LP acquired a new position in KalVista Pharmaceuticals in the 4th quarter valued at approximately $8,409,000. Finally, Vestal Point Capital LP increased its stake in KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after buying an additional 770,000 shares during the period.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total transaction of $517,440.51. Following the transaction, the chief executive officer owned 369,595 shares in the company, valued at approximately $5,798,945.55. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,942 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the transaction, the insider owned 119,841 shares in the company, valued at $1,584,298.02. This represents a 2.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,710 shares of company stock worth $880,764 in the last 90 days. 4.30% of the stock is owned by insiders.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock traded down $0.05 during midday trading on Monday, reaching $13.46. 436,472 shares of the company's stock traded hands, compared to its average volume of 635,500. The company has a market cap of $677.58 million, a price-to-earnings ratio of -3.65 and a beta of -0.10. The company's 50 day simple moving average is $13.50 and its 200 day simple moving average is $12.50. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.32.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the company posted ($1.07) EPS. As a group, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on KALV shares. JMP Securities upped their price objective on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a research note on Tuesday, July 8th. Leerink Partners upped their price objective on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Finally, HC Wainwright upped their price objective on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).